Danaher Co. (NYSE:DHR) Shares Purchased by O Brien Greene & Co. Inc

O Brien Greene & Co. Inc grew its position in Danaher Co. (NYSE:DHR) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,141 shares of the conglomerate’s stock after acquiring an additional 90 shares during the quarter. Danaher accounts for about 3.1% of O Brien Greene & Co. Inc’s holdings, making the stock its 6th largest position. O Brien Greene & Co. Inc’s holdings in Danaher were worth $8,823,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP lifted its position in shares of Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares during the period. Allen Investment Management LLC boosted its stake in shares of Danaher by 1,440.7% in the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock valued at $273,009,000 after purchasing an additional 1,028,976 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Danaher in the 3rd quarter worth about $178,850,000. Alecta Tjanstepension Omsesidigt acquired a new stake in shares of Danaher during the 4th quarter worth about $161,994,000. Finally, Harris Associates L P lifted its holdings in Danaher by 27.7% during the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock valued at $735,343,000 after purchasing an additional 642,759 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the completion of the transaction, the director now directly owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the transaction, the director now owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold 106,565 shares of company stock valued at $26,641,364 in the last 90 days. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 0.3 %

NYSE DHR opened at $246.58 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The stock has a 50-day simple moving average of $248.87 and a 200 day simple moving average of $231.08. The company has a current ratio of 1.85, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $182.64 billion, a PE ratio of 41.77, a P/E/G ratio of 3.78 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the firm earned $2.36 earnings per share. The business’s quarterly revenue was down 2.6% on a year-over-year basis. Research analysts forecast that Danaher Co. will post 7.65 EPS for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DHR shares. Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. KeyCorp lifted their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. TD Cowen increased their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and upped their price target for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Bank of America raised their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $270.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.